“This approval enables use of the approved Mounjaro pen in a more hassle-free presentation of a month’s treatment method, of one dose a week.”In April of 2022, Eli Lilly disclosed the preliminary success on the SURMOUNT-one clinical demo it experienced done. Over the 72-week MounjaroTM (Tirzepatide) demo, those with surplus weight or being ov